Journal club Update on systemic therapies in paediatric dermatology

Eur J Dermatol. 2021 Oct 1;31(5):672-675. doi: 10.1684/ejd.2021.4152.

Authors

Sophia Mohme¹, Neda Alband², Angel Rosell Diaz³, Marine-Alexia Lefevre⁴, Enrique Rodriguez Lomba³, Miguel Nogueira⁵, Matthias Goebeler¹, Henning Hamm¹

Affiliations

¹ Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
² Dermatology of Department, Cambridge University Hospitals, Addenbrookes Hospital, Cambridge, UK.
³ Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
⁴ CIRI, Centre International de Recherche en Infectiologie (Team Epidermal Immunity and Allergy); INSERM, U1111; Univ Lyon; Université de Lyon 1; Ecole Normale Supérieure de Lyon; CNRS, UMR 5308, Lyon, France Department of Dermatology and Allergology, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, France.
⁵ Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.

PMID: 34903508
DOI: 10.1684/ejd.2021.4152

No abstract available

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Antiparasitic Agents / adverse effects
Antiparasitic Agents / therapeutic use
Benzimidazoles / adverse effects
Benzimidazoles / therapeutic use
Child
Dermatologic Agents / adverse effects
Dermatologic Agents / therapeutic use*
Histiocytosis, Langerhans-Cell / drug therapy
Humans
Ivermectin / adverse effects
Ivermectin / therapeutic use
Netherton Syndrome / drug therapy
Neurofibromatosis 1 / drug therapy
Scabies / drug therapy
Skin Diseases / drug therapy*
Vemurafenib / adverse effects
Vemurafenib / therapeutic use

Substances

AZD 6244
Antibodies, Monoclonal, Humanized
Antiparasitic Agents
Benzimidazoles
Dermatologic Agents
Vemurafenib
Ivermectin
secukinumab